Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tpf induction chemotherapy response prediction in inoperable head and neck squamous cell carcinoma
2006-005537-38Phase 4Completed
- Sponsor
- CHU Nîmes
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by CHU Nîmes. Primary endpoints: Tumor response rate after 3 cycles of docetaxel, cisplatin, and fluorouracil and Predictive tumor transcriptional profile after first cycle. Started Jun 2007; status: completed.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-005537-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005537-38.